deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT04907968

Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer (UPGRADE)

Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A)

Sponsor: IQVIA Biotech

Conditions Platinum-sensitive Ovarian Cancer (UPGRADE-A)
Interventions Carboplatin XMT-1536 (Upifitamab Rilsodotin)
Updated 16 times since 2021 Last updated: Oct 6, 2023 Started: Jun 11, 2021 Primary completion: Oct 3, 2023 Completion: Oct 3, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study Terminated by Sponsor

Other terminated trials from IQVIA Biotech

See all terminations from IQVIA Biotech

A PHASE1 clinical study on Platinum-sensitive Ovarian Cancer (UPGRADE-A), this trial is terminated or withdrawn. The trial is conducted by IQVIA Biotech and has accumulated 16 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Apr 2022 · 5 months · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  4. Jul 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

▶ Show 11 earlier versions

  1. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  2. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1

  3. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1

    Phase: PHASE1_PHASE2 → PHASE1

  5. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  9. Nov 2021 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jun 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • IQVIA Biotech
  • Mersana Therapeutics
  • PSI CRO
Data source: Mersana Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations